myelodysplastic syndrome
In a small validation set, the model was able to make accurate predictions about patient outcomes using routinely collected patient data.
Syros Pharmaceuticals' Phase III Trial of Tamibarotene in MDS Fails to Meet Primary Endpoint
The firm said the tamibarotene-azacitidine combo did not significantly improve the complete response rate compared to placebo-azacitidine.
National Cancer Institute Launches MyeloMATCH Myeloid Cancer Treatment Clinical Trial
The trial aims to enroll several thousand patients to test precision medicine treatments for bone marrow and blood cancers.
Aptadir Therapeutics Launches With $1.6M to Advance RNA Inhibitors for Cancers, Genetic Conditions
The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Aug 14, 2020